Claims

1. Pharmaceutical composition for a sustained release of an active ingredient for at least 2 months, comprising:

- lanreotide as the active ingredient,
- a hydrosoluble co-solvent, and
- water,

the pH ranging from 4.0 to 7.5, wherein the co-solvent is present in a concentration ranging from 10 to 25 % by weight relative to the total weight of the composition and the concentration of lanreotide as a free base is ranging from 35 to 55 % by weight relative to the total weight of the composition.

2. Pharmaceutical composition according to claim 1, wherein the concentration of lanreotide as a free base is ranging from 40 to 50 % by weight relative to the total weight of the composition.

3. Pharmaceutical composition according to claim 1, wherein the concentration of lanreotide as a free base is ranging from 42 to 48 % by weight relative to the total weight of the composition.

4. Pharmaceutical composition according to claim 1, wherein lanreotide is in a salt form.

5. Pharmaceutical composition according to claim 1, wherein lanreotide is in the form of lanreotide acetate.

6. Pharmaceutical composition according to any one of the preceding claims, wherein the pH is ranging from 4.0 to 6.0, and more preferably from 4.8 to 5.4.

7. Pharmaceutical composition according to any one of the preceding claims, comprising a pH modifier.

8. Pharmaceutical composition according to claim 7, comprising a pH modifier which is different from the co-solvent.

9. Pharmaceutical composition according to claim 7 to 8, wherein the pH modifier is selected from acetic acid, citric acid, lactic acid, phosphoric acid, hydrochloric acid, stearic acid and

10. Pharmaceutical composition according to according to any one of the preceding claims, wherein the co-solvent is selected from N-methyl-2-pyrrolidone (NMP), propylene glycol, glycerol, low molecular weight polyethylene glycols (PEG), glycofurol, ethanol and a mixture thereof.

11. Pharmaceutical composition according to claim 10, wherein the co-solvent is selected from N-methyl-2-pyrrolidone (NMP), low molecular weight PEG, glycofurol and mixtures thereof.

12. Pharmaceutical composition according to claim 10, wherein the co-solvent is glycofurol.

13. Pharmaceutical composition according to claim 10, wherein the co-solvent is glycofurol and is present in a concentration ranging from 16 to 22 %.

14. Pharmaceutical composition according to any one of the preceding claims, which is free of any non hydrosoluble, biocompatible and/or biodegradable, (co)polymer.

15. Pharmaceutical composition according to any of the preceding claims, which contains other additives selected from stabilizers, antioxidants and surfactants.

16. Pharmaceutical composition according to claim 15, wherein the amount in weight of these additives is lower than 5.0 % of the pharmaceutical composition, preferably lower than 1.0 %.

17. Pharmaceutical composition according to any of the preceding claims, which is to be administered by the parenteral route.

18. Pharmaceutical composition according to any of the preceding claims, for a sustained release of at least 2 to 6 months in humans.

19. Pharmaceutical composition according to any of the preceding claims, for a sustained release of at least 3 months in humans.

20. Pharmaceutical composition according to any of the preceding claims, for use in the treatment of acromegaly or neuroendocrine tumors (NET).